

On page 9, line 38, after "Apo-2", insert --(SEQ ID NO:7)--.

On page 9, line 38, after "DR4", insert --(SEQ ID NO:8)--.

On page 9, line 38, after "Apo3/DR3", insert --(SEQ ID NO:9)--.

On page 9, line 38, after "TNFR1", insert --(SEQ ID NO:10)--.

On page 9, line 39, after "(CD95)", insert --(SEQ ID NO:11)--.

On page 58, line 12, after "(Fig. 2A", insert -- ;SEQ ID NO:6)--.

On page 58, line 16, after "Fig. 1", insert -- (SEQ ID NO:2)--.

On page 58, line 16, after "Fig. 2A", insert --(SEQ ID NO:6)--.

On page 58, line 18, after "DR4", insert --(SEQ ID NO:8)--.

On page 58, line 18, after "TNFR1", insert --(SEQ ID NO:10)--.

On page 58, line 18, after "CD95", insert --(SEQ ID NO:11)--.

On page 58, line 19, after "Apo-3/DR3", insert --(SEQ ID NO:9)--.

On page 58, line 25, after "DR4", insert --(SEQ ID NO:8)--.

On page 58, line 25, after "TNFR1", insert --(SEQ ID NO:10)--.

On page 58, line 26, after "CD95", insert --(SEQ ID NO:11)--.

On page 58, line 26, after "Apo-3", insert --(SEQ ID NO:9)--.

On page 58, line 32, after "Figure 1", insert --(SEQ ID NO:1)--.

On page 58, line 34, after "Figure 1", insert --(SEQ ID NO:1)--.

On page 59, line 9, after "Fig. 1", insert --(SEQ ID NO:1)--.

On page 64, line 20, after "Fig. 1", insert --;SEQ ID NO:1--.

Please enter into the Specification the substitute Sequence Listing (pages 1-9) attached hereto.

REMARKS

In the Office Action, the Examiner required restriction under 35 USC Section 121 to one of three groups of claims (Group I-claims 1-10, 12 and 15-18, Group II-claim 11, and Group III-claim 14). Applicants hereby elect to prosecute in the present application the claims of Group I drawn to an antibody that binds Apo-2. Claims 11 and 14, being drawn to the non-elected invention, were canceled in the above amendment without prejudice.